Therapy Directory

Fulvestrant clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention. Browse Fulvestrant recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

294

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Fulvestrant, Tamoxifen; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Fulvestrant with Enzalutamide; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Lone Tree, Colorado • Germantown, Tennessee

Conditions: Breast Cancer
Interventions: Fulvestrant, GDC-0810; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 4 more

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, erlotinib, Placebo; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 6
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Springdale, Arkansas + 3 more

Conditions: Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
Interventions: SY-1365 (Part 1), Carboplatin, Fulvestrant, SY-1365 (Cohort 2), SY-1365 (Cohort 5), SY-1365 (Part 2 Single Agent); Drug
Lead sponsor: Syros Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Francisco, California + 11 more

Conditions: Breast Cancer
Interventions: Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 223
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more

Conditions: Breast Cancer
Interventions: anastrozole, fulvestrant; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 418
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 289 more

Conditions: Solid Tumors and Lymphomas
Interventions: Alobresib, Exemestane, Fulvestrant; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more

Conditions: Breast Cancer
Interventions: LEE011, BYL719, fulvestrant, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Faslodex, Herceptin; Drug · Biological
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Redondo Beach, California • San Antonio, Texas

Conditions: Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
Interventions: BYL719, Fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Metastatic Breast Cancer
Interventions: Seribantumab, Fulvestrant, Placebo; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 19 more

About this Fulvestrant clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Fulvestrant as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Fulvestrant.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Fulvestrant clinical trials

Filter and sort this therapy

Live official records

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

About this Fulvestrant clinical trials directory page